Rhythm Control - Catheter Ablation With or Without Anti-arrhythmic Drug Control of Maintaining Sinus Rhythm Versus Rate Control With Medical Therapy and/or Atrio-ventricular Junction Ablation and Pacemaker Treatment for Atrial Fibrillation

Inclusion Criteria: 1. Patients with one of the following AF categories and at least one ECG documentation of AF * High burden Paroxysmal defined as ≥ 4 episodes of AF in the last 6 months, and at least one episode \> 6 hours (and no episode requiring cardioversion and no episode \> 7 days) * Persistent AF (1) defined as ≥ 4 episodes of AF in the last 6 months, and at least one episode \> 6 hours, and at least one AF episode less than 7 days but requires cardioversion. No AF episodes are \> 7 days * Persistent AF (2) as defined by at least one episode of AF \> 7 days but not \> 1 year * Long term persistent AF defined as an AF episode, at least one year in length and no episodes \> 3 years 2. Optimal therapy for heart failure of at least 6 weeks (according to 2009 ACCF/AHA class 1 recommendations). 3. HF with NYHA class II or III symptoms with either impaired LV function (LVEF ≤ 45%) as determined by EF assessment within the previous 12 months or preserved LV function (LVEF \> 45%) determined by by EF assessment within the previous 12 months 4. NT-pro BNP measures: A) Patient has been hospitalized for Heart Failure\* in the past 9 months, has been discharged AND: i- Is presently in Normal Sinus Rhythm and NT-pro BNP is ≥ 400 pg/mL ii- Is presently in Atrial Fibrillation and NT-pro BNP is ≥ 600 pg/mL OR B) Patient has had no hospitalization for Heart Failure in the past 9 months AND: i- Has had paroxysmal Atrial Fibrillation, is presently in Normal Sinus Rhythm and NT-proBNP is ≥ 600 pg/mL ii- Is presently in Atrial Fibrillation and NT-proBNP is ≥ 900 pg/mL \*Heart Failure Admission is defined as admission to hospital \> 24 hours and received treatment for Heart failure 5. Suitable candidate for catheter ablation or rate control therapy for the treatment of AF 6. Age ≥18 Exclusion Criteria: 1. Have an LA dimension \> 55 mm as determined by an echocardiography within the previous year 2. Had an acute coronary syndrome or coronary artery bypass surgery within 12 weeks 3. Have rheumatic heart disease, severe aortic or mitral valvular heart disease using the AHA/ACC guidelines 4. Have congenital heart disease including previous ASD repair, persistent left superior vena cava 5. Had prior surgical or percutaneous AF ablation procedure or atrioventricular nodal (AVN) ablation 6. Have a medical condition likely to limit survival to \< 1 year 7. Have New York Heart Association (NYHA) class IV heart failure symptoms 8. Have contraindication to systematic anticoagulation 9. Have renal failure requiring dialysis 10. AF due to reversible cause e.g. hyperthyroid state 11. Are pregnant 12. Are included in other clinical trials that will affect the objectives of this study 13. Have a history of non-compliance to medical therapy 14. Are unable or unwilling to provide informed consent